Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Michael Bristow to Aged

This is a "connection" page, showing publications Michael Bristow has written about Aged.

 
Connection Strength
  
 
 
1.059
  
  1. Shamoun F, De Marco T, DeMets D, Mei C, Lindenfeld J, Saxon LA, Boehmer JP, Leigh J, Yong P, Feldman AM, Bristow MR. Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC Heart Fail. 2019 04; 7(4):281-290.
    View in: PubMed
    Score: 0.045
  2. Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 08; 11(8):e002210.
    View in: PubMed
    Score: 0.044
  3. Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 05; 199:51-58.
    View in: PubMed
    Score: 0.042
  4. Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 01 15; 121(2):256-261.
    View in: PubMed
    Score: 0.041
  5. Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in?the?Design, Analysis, and Outcomes of?the COMPANION Trial. JACC Heart Fail. 2016 07; 4(7):521-535.
    View in: PubMed
    Score: 0.038
  6. Lindenfeld J, Cleveland JC, Kao DP, White M, Wichman S, Bristow JC, Peterson V, Rodegheri-Brito J, Korst A, Blain-Nelson P, Sederberg J, Hunt SA, Gilbert EM, Ambardekar AV, Minobe W, Port JD, Bristow MR. Sex-related differences in age-associated downregulation of human ventricular myocardial ?1-adrenergic receptors. J Heart Lung Transplant. 2016 Mar; 35(3):352-361.
    View in: PubMed
    Score: 0.036
  7. Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med. 2014 Oct; 127(10):963-71.
    View in: PubMed
    Score: 0.033
  8. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar; 15(3):324-33.
    View in: PubMed
    Score: 0.030
  9. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and ?1, a2C adrenergic receptor polymorphisms. PLoS One. 2012; 7(10):e44324.
    View in: PubMed
    Score: 0.029
  10. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR. Influence of global region on outcomes in heart failure ?-blocker trials. J Am Coll Cardiol. 2011 Aug 23; 58(9):915-22.
    View in: PubMed
    Score: 0.027
  11. Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010 Nov-Dec; 16(6):265-70.
    View in: PubMed
    Score: 0.025
  12. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010 Jan; 3(1):21-8.
    View in: PubMed
    Score: 0.024
  13. Sumner AD, Boehmer JP, Saxon LA, Carson P, Feldman AM, Galle E, Bristow MR. Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy. Congest Heart Fail. 2009 Jul-Aug; 15(4):159-64.
    View in: PubMed
    Score: 0.023
  14. Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G, Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol. 2009 Jul; 20(7):764-8.
    View in: PubMed
    Score: 0.023
  15. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009 Feb 24; 119(7):969-77.
    View in: PubMed
    Score: 0.023
  16. Sharkey SW, Maron BJ, Nelson P, Parpart M, Maron MS, Bristow MR. Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol. 2009 Feb; 53(1):53-7.
    View in: PubMed
    Score: 0.022
  17. De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, Wagoner L, Kirlin PC, Kennett JD, Goel S, Saxon LA, Boehmer JP, Mann D, Galle E, Ecklund F, Yong P, Bristow MR. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008 Feb; 14(1):9-18.
    View in: PubMed
    Score: 0.021
  18. Sauer WH, Bristow MR. The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective. J Interv Card Electrophysiol. 2008 Jan; 21(1):3-11.
    View in: PubMed
    Score: 0.021
  19. Metra M, Dei Cas L, Bristow MR. The pathophysiology of acute heart failure--it is a lot about fluid accumulation. Am Heart J. 2008 Jan; 155(1):1-5.
    View in: PubMed
    Score: 0.021
  20. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail. 2007 Nov; 13(9):769-73.
    View in: PubMed
    Score: 0.021
  21. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinberg JS, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007 Jan 16; 115(2):204-12.
    View in: PubMed
    Score: 0.020
  22. Lowes BD, Zolty R, Minobe WA, Robertson AD, Leach S, Hunter L, Bristow MR. Serial gene expression profiling in the intact human heart. J Heart Lung Transplant. 2006 May; 25(5):579-88.
    View in: PubMed
    Score: 0.019
  23. Bristow MR, Adams KF, Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann DL, Talbert RL. The COMET trial. Congest Heart Fail. 2005 Jan-Feb; 11(1):39-47.
    View in: PubMed
    Score: 0.017
  24. Pittenger B, Gill EA, Holcslaw TL, Bristow MR. Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. Am J Cardiol. 2004 Dec 01; 94(11):1459-62.
    View in: PubMed
    Score: 0.017
  25. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004 Sep 14; 110(11):1437-42.
    View in: PubMed
    Score: 0.017
  26. Mallabone M, Labib D, Abdelhaleem A, Dykstra S, Thompson RB, Paterson DI, Thompson SK, Hasanzadeh F, Mikami Y, Rivest S, Flewitt J, Feng Y, Macdonald M, King M, Bristow M, Kolman L, Howarth AG, Lydell CP, Miller RJH, Fine NM, White JA. Sex-based differences in the phenotypic expression and prognosis of idiopathic non-ischaemic cardiomyopathy: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2024 May 31; 25(6):804-813.
    View in: PubMed
    Score: 0.016
  27. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20; 350(21):2140-50.
    View in: PubMed
    Score: 0.016
  28. Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, de Mets D. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. Eur J Heart Fail. 2022 06; 24(6):1080-1090.
    View in: PubMed
    Score: 0.014
  29. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 02; 346(18):1357-65.
    View in: PubMed
    Score: 0.014
  30. Purmah Y, Cornhill A, Lei LY, Dykstra S, Mikami Y, Satriano A, Labib D, Flewitt J, Rivest S, Sandonato R, Seib M, Howarth AG, Lydell CP, Heydari B, Merchant N, Bristow M, Kolman L, Fine NM, White JA. Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy. Sci Rep. 2022 02 02; 12(1):1739.
    View in: PubMed
    Score: 0.014
  31. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
    View in: PubMed
    Score: 0.014
  32. Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, Aleong R, Krueger SK, Sauer WH, Wilton SB, Rienstra M, van Veldhuisen DJ, Anand IS, White M, Camm AJ, Ziegler PD, Marshall D, Bristow MR, Connolly SJ. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 08; 14(8):e009591.
    View in: PubMed
    Score: 0.013
  33. Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, Pitt B, Shah SJ, Vardeny O, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Spironolactone in Patients With Heart?Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 03 09; 77(9):1211-1221.
    View in: PubMed
    Score: 0.013
  34. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol. 2000 Aug; 36(2):501-8.
    View in: PubMed
    Score: 0.013
  35. Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
    View in: PubMed
    Score: 0.012
  36. Gerdes AM, Onodera T, Tamura T, Said S, Bohlmeyer TJ, Abraham WT, Bristow MR. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail. 1998 Dec; 4(4):343-8.
    View in: PubMed
    Score: 0.011
  37. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998 Jan 15; 81(2):247-50.
    View in: PubMed
    Score: 0.011
  38. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:291-6.
    View in: PubMed
    Score: 0.010
  39. Kalscheur MM, Saxon LA, Lee BK, Steinberg JS, Mei C, Buhr KA, DeMets DL, Bristow MR, Singh SN. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. Heart Rhythm. 2017 06; 14(6):858-865.
    View in: PubMed
    Score: 0.010
  40. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
    View in: PubMed
    Score: 0.010
  41. Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD, Shea S, Weiss NS, Kronmal RA. Histamine H2 Receptor Antagonists, Left?Ventricular Morphology, and Heart?Failure?Risk: The MESA Study. J Am Coll Cardiol. 2016 Apr 05; 67(13):1544-1552.
    View in: PubMed
    Score: 0.009
  42. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, Renlund D, Mealey P, Abraham WT, Bristow MR. Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1995 Dec 15; 76(17):1271-6.
    View in: PubMed
    Score: 0.009
  43. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
    View in: PubMed
    Score: 0.009
  44. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May; 25(6):1225-31.
    View in: PubMed
    Score: 0.009
  45. Feldman AM, She L, McNamara DM, Mann DL, Bristow MR, Maisel AS, Wagner DR, Andersson B, Chiariello L, Hayward CS, Hendry P, Parker JD, Racine N, Selzman CH, Senni M, Stepinska J, Zembala M, Rouleau J, Velazquez EJ, Lee KL. Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. Cardiology. 2015; 130(2):69-81.
    View in: PubMed
    Score: 0.009
  46. Abraham WT, Lowes BD, White M, Ferguson DA, Scheffel CA, Wolfel EE, Lindenfeld J, Bristow MR. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. J Card Fail. 1994 Oct; 1(1):57-62.
    View in: PubMed
    Score: 0.008
  47. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994 Jul-Aug; 13(4):S107-12.
    View in: PubMed
    Score: 0.008
  48. Leary PJ, Barr RG, Bluemke DA, Bristow MR, Hough CL, Kronmal RA, Lima JA, McClelland RL, Tracy RP, Kawut SM. Von Willebrand factor and the right ventricle (the MESA-Right Ventricle Study). Am J Cardiol. 2012 Dec 15; 110(12):1846-51.
    View in: PubMed
    Score: 0.007
  49. Kawut SM, Barr RG, Lima JA, Praestgaard A, Johnson WC, Chahal H, Ogunyankin KO, Bristow MR, Kizer JR, Tandri H, Bluemke DA. Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)--right ventricle study. Circulation. 2012 Oct 02; 126(14):1681-8.
    View in: PubMed
    Score: 0.007
  50. Dibble CT, Lima JAC, Bluemke DA, Chirinos JA, Chahal H, Bristow MR, Kronmal RA, Barr RG, Ferrari VA, Propert KJ, Kawut SM. Regional left ventricular systolic function and the right ventricle: the multi-ethnic study of atherosclerosis right ventricle study. Chest. 2011 Aug; 140(2):310-316.
    View in: PubMed
    Score: 0.007
  51. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, Cappola AR, Bristow MR, Johnson C, Kronmal RA, Kizer JR, Lima JA, Kawut SM. Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):659-67.
    View in: PubMed
    Score: 0.006
  52. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar; 88(3):223-9.
    View in: PubMed
    Score: 0.006
  53. Metra M, Eichhorn E, Abraham WT, Linseman J, B?hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009 Dec; 30(24):3015-26.
    View in: PubMed
    Score: 0.006
  54. Taylor MR, Slavov D, Humphrey K, Zhao L, Cockroft J, Zhu X, Lavori P, Bristow MR, Mestroni L, Lazzeroni LC. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics. 2009 Jan; 19(1):35-43.
    View in: PubMed
    Score: 0.006
  55. MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
    View in: PubMed
    Score: 0.006
  56. Haddad GE, Saunders LJ, Crosby SD, Carles M, del Monte F, King K, Bristow MR, Spinale FG, Macgillivray TE, Semigran MJ, Dec GW, Williams SA, Hajjar RJ, Gwathmey JK. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. Physiol Genomics. 2008 Apr 22; 33(2):267-77.
    View in: PubMed
    Score: 0.005
  57. Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML, Maxey ML, McCune SA, Moore RL. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res. 2007 Jul; 48(7):1559-70.
    View in: PubMed
    Score: 0.005
  58. Taylor MR, Slavov D, Ku L, Di Lenarda A, Sinagra G, Carniel E, Haubold K, Boucek MM, Ferguson D, Graw SL, Zhu X, Cavanaugh J, Sucharov CC, Long CS, Bristow MR, Lavori P, Mestroni L. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation. 2007 Mar 13; 115(10):1244-51.
    View in: PubMed
    Score: 0.005
  59. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation. 2006 Dec 19; 114(25):2766-72.
    View in: PubMed
    Score: 0.005
  60. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005 Dec; 11(9):693-9.
    View in: PubMed
    Score: 0.005
  61. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, Bristow MR, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail. 2004 Feb; 10(1):15-20.
    View in: PubMed
    Score: 0.004
  62. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003 Sep 03; 42(5):914-22.
    View in: PubMed
    Score: 0.004
  63. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer. 1982 Jul 01; 50(1):32-41.
    View in: PubMed
    Score: 0.004
  64. Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
    View in: PubMed
    Score: 0.003
  65. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
    View in: PubMed
    Score: 0.003
  66. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
    View in: PubMed
    Score: 0.003
  67. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med. 1978 Nov; 65(5):823-32.
    View in: PubMed
    Score: 0.003
  68. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun; 62(6):873-9.
    View in: PubMed
    Score: 0.003
  69. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998 Mar; 4(1):37-44.
    View in: PubMed
    Score: 0.003
  70. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978 Feb; 88(2):168-75.
    View in: PubMed
    Score: 0.003
  71. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 1997 Sep; 3(3):173-9.
    View in: PubMed
    Score: 0.003
  72. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 01; 94(11):2800-6.
    View in: PubMed
    Score: 0.002
  73. Renlund DG, Taylor DO, Ensley RD, O'Connell JB, Gilbert EM, Bristow MR, Ma H, Yanowitz FG. Exercise capacity after heart transplantation: influence of donor and recipient characteristics. J Heart Lung Transplant. 1996 Jan; 15(1 Pt 1):16-24.
    View in: PubMed
    Score: 0.002
  74. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993 Dec 11; 342(8885):1441-6.
    View in: PubMed
    Score: 0.002
  75. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993 Oct 30; 342(8879):1073-5.
    View in: PubMed
    Score: 0.002
  76. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993 Jul 15; 329(3):149-55.
    View in: PubMed
    Score: 0.002
  77. Olsen SL, Wagoner LE, Hammond EH, Taylor DO, Yowell RL, Ensley RD, Bristow MR, O'Connell JB, Renlund DG. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant. 1993 Mar-Apr; 12(2):S135-42.
    View in: PubMed
    Score: 0.002
  78. Schroeder JS, Beier-Scott L, Ginsburg R, Bristow MR, McAuley BJ. Efficacy of diltiazem for medically refractory stable angina: long-term follow-up. Clin Cardiol. 1985 Sep; 8(9):480-5.
    View in: PubMed
    Score: 0.001
  79. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW, Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983 Dec; 99(6):745-9.
    View in: PubMed
    Score: 0.001
  80. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov; 106(5 Pt 1):1048-56.
    View in: PubMed
    Score: 0.001
  81. Schroeder JS, Lamb IH, Bristow MR, Ginsburg R, Hung J, McAuley BJ. Prevention of cardiovascular events in variant angina by long-term diltiazem therapy. J Am Coll Cardiol. 1983 Jun; 1(6):1507-11.
    View in: PubMed
    Score: 0.001
  82. Schroeder JS, Lamb IH, Ginsburg R, Bristow MR, Hung J. Diltiazem for long-term therapy of coronary arterial spasm. Am J Cardiol. 1982 Feb 18; 49(3):533-7.
    View in: PubMed
    Score: 0.001
  83. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978 Jun; 62(6):857-64.
    View in: PubMed
    Score: 0.001
  84. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun; 62(6):865-72.
    View in: PubMed
    Score: 0.001
  85. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol. 1977 Mar; 1(1):17-23.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)